论文部分内容阅读
目的 :探讨α颗粒膜蛋白 (CD62 P)和溶酶体膜蛋白 (CD63 )活化表达对老年糖尿病肾病早期诊断和病情监测的临床价值。方法 :采用流式细胞仪测定 196例老年 2型糖尿病患者 (其中单纯糖尿病 94例 ,糖尿病肾病 10 2例 )血浆CD62 P和CD63 水平 ,并与 40例健康人进行比较。同时观察糖尿病肾病血糖控制后CD62 P和CD63 的变化。结果 :单纯糖尿病组CD62 P和CD63 高于健康人组 (P <0 .0 0 1) ,糖尿病肾病组高于单纯糖尿病组 (P <0 .0 0 1) ,对糖尿病肾病患者进行血糖控制和抗凝治疗 6个月后 ,CD62 P、CD63 和 2 4h尿白蛋白排泄率 (UAER)水平下降 ,与对照组比较有显著性差异。结论 :CD62 P和CD63 对老年糖尿病肾病的早期诊断和病情监测有重要的临床价值
Objective: To investigate the clinical value of the activation of CD62P and CD63 on early diagnosis and condition monitoring of senile diabetic nephropathy. Methods: The plasma levels of CD62P and CD63 in 196 elderly type 2 diabetic patients (94 simple diabetic patients and 102 diabetic nephropathy patients) were determined by flow cytometry and compared with 40 healthy subjects. At the same time observe the changes of CD62P and CD63 in diabetic nephropathy after glycemic control. Results: The levels of CD62P and CD63 in diabetic group were significantly higher than those in healthy group (P <0.01), those in diabetic nephropathy group were higher than those in simple diabetic group (P <0.01) After 6 months of anticoagulant therapy, the levels of urinary albumin excretion (UAER) of CD62 P, CD63 and 24 hours decreased significantly compared with the control group. Conclusion: CD62 P and CD63 have important clinical value in early diagnosis and condition monitoring of senile diabetic nephropathy